Following on from the successes of the World Epigenetics Summit series, the world’s largest commercially focussed epigenetics meeting is growing to reflect and accelerate this development.
The meeting has been designed in collaboration with thought leaders at GSK, EpiZyme, Constellation, Pfizer, Genentech, Celgene, Abbvie, Gilead,Acetylon, and many more. EpiCongress will not only help you to understand the basic mechanisms behind genome regulation and chromatin function. It will also address the most pressing clinical considerations to ensure the success of current and future candidates.
Hear from 50 expert speakers from across pharma, biotechs and research institutes presenting their most promising data. Capture the last 12 months of progress by hearing how epigenetic candidates have been performing across the board. And access the translational science with the potential to transform your drug discovery.
EpiGenie users can register for the meeting with 10% off standard prices. Simply quote “EPIGENIE” when registering to secure your place.
Attend the FUNDAMENTAL EPIGENETICS stream to:
- Learn about genome regulation to explore the therapeutic opportunities in altered epigenomic states
- Explore the biology and pharmacological properties behind selected HMT and demethylases compounds
- Get to grips with heterogeneity in neuropsychiatric disorders to see how it can impact your therapeutic strategies
Get the latest from the EPIGENTIC INNOVATIONS stream:
- Get an insight into unpublished data from the industry’s exciting EZH2 programs
- Understand the chemistry behind LSD1 histone methyltransferases and demethylases to develop potent and specific small molecule inhibitors
- Improve your target validation by identifying which inhibitors are ticking all the boxes for pharma
Take part in the discussions during the EPIGENETICS IN THE CLINIC stream to:
- Choose the most effective biomarker strategies for your program and discuss what clinical biomarkers will look like for novel epigenetic drugs
- Discover how companies are currently selecting their PK/ PD endpoints for early clinical trials
- Learn from those who have achieved successful patient selection so far in phase 1 and 2